Content about Royalties

February 26, 2013
Reports: Elan not responding to acquisition offer from Royalty Pharma

A privately owned drug maker in New York is offering $6.5 billion for Irish drug maker Elan Corp., but hasn't heard back from it, according to published reports.

February 8, 2013
Elan sells Tysabri rights to Biogen Idec

Elan will sell the rights to its drug for multiple sclerosis to partnering company Biogen Idec for $3.25 billion plus royalties, the Irish drug maker said.

April 3, 2012
Forest buys rights to Bystolic from J&J

Forest Labs has bought rights to a drug used for high blood pressure that it had marketed with a Johnson & Johnson subsidiary, thus eliminating the need to pay future royalties.

August 15, 2011
Elizabeth Arden, Liz Claiborne amend licensing agreement

Elizabeth Arden has amended its long-term license agreement with Liz Claiborne to acquire the trademarks for the Curve fragrance brands and selected other smaller fragrance brands.

April 13, 2011
FDA accepts regulatory application for Bio-T-Gel

The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

February 7, 2011
Salix, Progenics ink licensing deal for Relistor

Salix Pharmaceuticals and Progenics Pharmaceuticals have entered a licensing agreement for a drug used to treat side effects of opioid use.

September 22, 2010
Abbott, Reata ink deal for chronic kidney disease treatment

Drug makers Abbott and Reata Pharmaceuticals have signed an agreement concerning a drug for chronic...

August 29, 2010
Somaxon, P&G to co-promote Silenor

A drug maker and a consumer packaged goods company will co-promote a newly approved insomnia...

March 30, 2010
AstraZeneca, Rigel get green light for licensing partnership

A licensing agreement between AstraZeneca and Rigel Pharmaceuticals for a rheumatoid arthritis treatment has gone...

© 2013 Drug Store News. All Rights Reserved.